Pemphigus Vulgaris – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Pemphigus Vulgaris – Pipeline Review, H1 2020’, provides an overview of the Pemphigus Vulgaris pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pemphigus Vulgaris, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pemphigus Vulgaris and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Pemphigus Vulgaris

– The report reviews pipeline therapeutics for Pemphigus Vulgaris by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Pemphigus Vulgaris therapeutics and enlists all their major and minor projects

– The report assesses Pemphigus Vulgaris therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Pemphigus Vulgaris

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Pemphigus Vulgaris

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Pemphigus Vulgaris pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alexion Pharmaceuticals Inc

Argenx SE

Biogen Inc

Cabaletta Bio Inc

Daewoong Pharmaceutical Co Ltd

Declion Pharmaceuticals Inc

HanAll Biopharma Co Ltd

iBio Inc

Novartis AG

Octagon Therapeutics Inc

Pharmapraxis

Principia Biopharma Inc

Topas Therapeutics GmbH

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Pemphigus Vulgaris - Overview

Pemphigus Vulgaris - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Pemphigus Vulgaris - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Pemphigus Vulgaris - Companies Involved in Therapeutics Development

Alexion Pharmaceuticals Inc

Argenx SE

Biogen Inc

Cabaletta Bio Inc

Daewoong Pharmaceutical Co Ltd

Declion Pharmaceuticals Inc

HanAll Biopharma Co Ltd

iBio Inc

Novartis AG

Octagon Therapeutics Inc

Pharmapraxis

Principia Biopharma Inc

Topas Therapeutics GmbH

Pemphigus Vulgaris - Drug Profiles

batoclimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Immunotherapy for Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPC-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DWP-212525 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

efgartigimod alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target DSG1 and DSG3 for Mucocutaneous Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target DSG3 for Pemphigus Vulgaris - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ianalumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

orilanolimab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OW-177 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rilzabrutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biobetter - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rituximab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPM-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Pemphigus Vulgaris - Dormant Projects

Pemphigus Vulgaris - Discontinued Products

Pemphigus Vulgaris - Product Development Milestones

Featured News & Press Releases

May 06, 2020: Cabaletta Bio receives FDA Fast Track Designation for DSG3-CAART for the treatment of Mucosal Pemphigus Vulgaris

Jan 29, 2020: FDA grants DSG3-CAART orphan drug designation for the treatment of pemphigus vulgaris

Dec 18, 2019: Topas Therapeutics announces first patient enrolled in phase 1 trial with TPM203 in pemphigus vulgaris

Oct 14, 2019: Roche’s Rituxan outperforms MMF in pemphigus vulgaris study

Oct 01, 2019: Cabaletta Bio receives IND clearance from FDA to initiate first clinical trial of DSG3-CAART in patients with Mucosal Pemphigus Vulgaris

Jun 12, 2019: Phase III PEMPHIX study showed that Genentech's Rituxan (Rituximab) is superior to standard of care in achieving sustained remission in patients with Pemphigus Vulgaris

Mar 15, 2019: EC approves Roche’s MabThera for pemphigus vulgaris

Mar 02, 2019: Principia Biopharma announces positive data from phase 2 pemphigus vulgaris trial at 2019 American Academy of Dermatology Annual Meeting in Late-Breaking Presentation

Feb 22, 2019: Principia Biopharma announces the acceptance of data from phase 2 Pemphigus Vulgaris trial as a late-breaking presentation at 2019 American Academy of Dermatology meeting

Jan 31, 2019: CHMP recommended extension of indication for Mabthera

Dec 12, 2018: Cell therapy industry pioneer, Gwendolyn Binder, Ph.D., to join Cabaletta Bio leadership team

Jul 24, 2018: argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation

Jun 20, 2018: argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris

Jun 14, 2018: argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation

Jun 07, 2018: FDA Approves Genentech's Rituxan (rituximab) For Pemphigus Vulgaris

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Pemphigus Vulgaris, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Pemphigus Vulgaris – Pipeline by Alexion Pharmaceuticals Inc, H1 2020

Pemphigus Vulgaris – Pipeline by Argenx SE, H1 2020

Pemphigus Vulgaris – Pipeline by Biogen Inc, H1 2020

Pemphigus Vulgaris – Pipeline by Cabaletta Bio Inc, H1 2020

Pemphigus Vulgaris – Pipeline by Daewoong Pharmaceutical Co Ltd, H1 2020

Pemphigus Vulgaris – Pipeline by Declion Pharmaceuticals Inc, H1 2020

Pemphigus Vulgaris – Pipeline by HanAll Biopharma Co Ltd, H1 2020

Pemphigus Vulgaris – Pipeline by iBio Inc, H1 2020

Pemphigus Vulgaris – Pipeline by Novartis AG, H1 2020

Pemphigus Vulgaris – Pipeline by Octagon Therapeutics Inc, H1 2020

Pemphigus Vulgaris – Pipeline by Pharmapraxis, H1 2020

Pemphigus Vulgaris – Pipeline by Principia Biopharma Inc, H1 2020

Pemphigus Vulgaris – Pipeline by Topas Therapeutics GmbH, H1 2020

Pemphigus Vulgaris – Dormant Projects, H1 2020

Pemphigus Vulgaris – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Pemphigus Vulgaris, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports